The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.
06. November 2026
The European Commission has published the fifth Joint Clinical Assessment (JCA), covering camizestrant (Etcamah) for the treatment of breast cancer. The assessment was prepared under the lead of Austria and …
05. November 2026
Berlin, 5 November 2026
Thomas Müller, Head of Department 1 at the Federal Ministry of Health (BMG) and responsible for medicinal products, made the case for further developing the early …
05. November 2026
Berlin, 5 November 2026
The Federal Joint Committee (GBA) has decided on the added benefit of the new medicinal product tovorafenib and, for the first time, has taken a European …
Key data from all AMNOG decisions, summarized in a compact and structured format.
Analyze your own research questions by filtering across more than 120 parameters.
Fast, quality-assured analysis of original documents such as dossiers, G-BA decisions, arbitration rulings, and clinical trials.
Price trends for all AMNOG drugs at PZN level and for annual therapy costs. Tracking of all appropriate comparator therapies (ZVT) and their weighting (on request).
EU dossiers and JCAs will be integrated into the AMNOG-Monitor as soon as the first ones become available.
Export analysis results to Excel, PowerPoint, or Word with links back to the AMNOG-Monitor. Save standard queries for price changes or new indications using bookmarks.
